Cumberland Pharmaceuticals (NASDAQ:CPIX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a report published on Wednesday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Stock Performance

Shares of Cumberland Pharmaceuticals stock opened at $1.76 on Wednesday. The company has a current ratio of 1.28, a quick ratio of 1.11 and a debt-to-equity ratio of 0.44. The business has a 50-day moving average price of $1.84 and a two-hundred day moving average price of $1.88. Cumberland Pharmaceuticals has a 1-year low of $1.43 and a 1-year high of $2.36. The company has a market cap of $24.96 million, a P/E ratio of -4.00 and a beta of 0.16.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last released its quarterly earnings data on Tuesday, March 5th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter. The company had revenue of $9.35 million for the quarter. Cumberland Pharmaceuticals had a positive return on equity of 6.84% and a negative net margin of 15.87%.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

A hedge fund recently bought a new stake in Cumberland Pharmaceuticals stock. Bank of New York Mellon Corp acquired a new position in shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 75,268 shares of the specialty pharmaceutical company’s stock, valued at approximately $142,000. Bank of New York Mellon Corp owned approximately 0.52% of Cumberland Pharmaceuticals at the end of the most recent reporting period. 15.51% of the stock is currently owned by hedge funds and other institutional investors.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.